Upsher Smith Company Profile

✉ Email this page to a colleague

UPSHER SMITH has ninety-seven approved drugs.

There are eight US patents protecting UPSHER SMITH drugs.

There are seventeen patent family members on UPSHER SMITH drugs in ten countries and one hundred and forty-two supplementary protection certificates in fourteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-005	Mar 11, 2014	AB2	RX	Yes	Yes	10,363,224	⤷ Try a Trial				⤷ Try a Trial
Upsher Smith Labs	ORVATEN	midodrine hydrochloride	TABLET;ORAL	076725-001	Nov 3, 2004	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Upsher Smith Labs	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	075566-002	Mar 8, 2004		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	RE43580	⤷ Try a Trial
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	6,440,392	⤷ Try a Trial
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	RE40812	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	➤ Subscribe	2015-12-24
➤ Subscribe	Nasal Spray	200 IU/spray	➤ Subscribe	2006-03-29

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015089289	⤷ Try a Trial
European Patent Office	2968177	⤷ Try a Trial
European Patent Office	3079703	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0780390	PA2004012,C0780390	Lithuania	⤷ Try a Trial	PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309
0392059	2002C/035	Belgium	⤷ Try a Trial	PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
0350733	C300111	Netherlands	⤷ Try a Trial	PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.